samedan logo
 
 
 
spacer
home > ebr > autumn 2001 > amyloid - those deadly fibrils
PUBLICATIONS
European Biopharmaceutical Review

Amyloid - Those Deadly Fibrils

<p align="justify" class="feature">The term 'amyloid' was introduced in scientific literature in the mid-19th Century to describe macroscopic abnormalities in organs and tissues of patients afflicted with a variety of clinical syndromes. It took almost a century to realise that these amyloid deposits consisted of fibrillar ultrastructures when examined by electron microscopy (see Figure 1).
Subsequently, numerous studies followed which confirmed that deposits of diverse origin show a similar, fibrillar submicroscopic structure consisting of bundles of straight and rigid fibrils. Several amyloid disorders have since been discovered. Although diverse in etiology and pathogenesis, they all demonstrate this accumulation of large fibrillary protein aggregates which interfere with specificorgan functions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Francine Gervais, Vice-President of Research & Development at Neurochem Inc.

As Vice-President of Research and Development, Dr Francine Gervais oversees Neurochem's R&D programme, bringing compounds from discovery through to drug development. Francine came to Neurochem with 15 years' experience in amyloid-related research as an Associate Professor at McGill University. She has been involved in determining the mechanisms responsible for the resistance or susceptibility to disease, including amyloidosis, bacterial and viral infections. Over the years, she has interacted with internationally-renowned research groups on the study of the genetic control of the host response to inflammatory and infectious diseases. Francine holds a PhD in Microbiology and Immunology from the University of Montréal. She began her career with Neurochem as a Consultant, and then joined the company on a full-time basis in June 1997.

spacer
Dr Francine Gervais
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avantor® Enters into Distribution Agreement to Supply Agilent Technologies’ Chemistries and Supplies Division products in the U.S. and Canada

Enabling analytical chemistry workflow laboratories full access to Agilent Technologies’ Chemistries & Supplies Division (CSD) portfolio - focusing on chromatography columns, sample preparation products, chemical standards, and spectroscopy supplies through Avantor’s leading digital and direct channels.
More info >>

White Papers

Future-proofing serialization solutions: the importance of strong level 3 capabilities

Adents

The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Around the world – in Europe and Asia in particular – disparate track and trace practices are incrementally moving toward a global standard that will, undoubtedly, be more stringent than today’s differing benchmarks. How can companies manage this transformation with the greatest degree of success while also minimizing business disruption? The key to creating an optimal implementation strategy is to select a serialization solution that has strong capabilities at all levels of technology. It’s also important to choose a solution that enables multi-phase implementation
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement